Loading
Life sciences · Journal article
Climacteric · October 8, 2026
No summary has been generated for this record yet. What follows is drawn from its source metadata only.
Journal article.
No findings were extractable from the material analysed.
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
The source did not state who this applies to in practice.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
This record has not been graded across any dimension yet. Treat the label above as provisional and read the source.
What is missing. This record has no bottom line, key findings, reported figures, evidence dimensions. That is a gap in the analysis, not a judgement about the study.
Perimenopause and early postmenopause represent a critical metabolic transition with adverse changes in body composition, insulin sensitivity, lipid metabolism and cardiometabolic health, contributing to increased rates of obesity, type 2 diabetes and cardiovascular disease. As the prevalence of obesity continues to rise among midlife women, effective therapeutic strategies are increasingly needed. Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) have emerged as highly effective treatments for obesity and type 2 diabetes through their effects on appetite regulation, weight reduction, glucose homeostasis and metabolic health. Beyond their established role, GLP-1 RAs have demonstrated favorable effects on visceral adiposity, glycemic control, lipid profiles, hepatic steatosis and cardiovascular outcomes. Preliminary experimental evidence also suggests possible complementary effects when combined with menopausal hormone therapy (MHT). However, menopause-specific evidence remains limited. This review summarizes the current evidence regarding the efficacy, safety and clinical application of GLP-1 RAs in perimenopausal and early postmenopausal women. Particular attention is given to their effects on cardiometabolic health, cardiovascular risk, bone and muscle health, cancer risk, cognition and potential interactions with MHT. Although GLP-1 RAs represent a promising therapeutic option for obesity and metabolic dysfunction during menopause, important knowledge gaps remain regarding their long-term safety, effects on menopause-related outcomes and optimal integration into comprehensive menopausal care. The efficacy, safety and potential interactions of GLP-1 RAs when used in combination with MHT remain to be determined.